Long‐term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)

• Published in: BJU international Vol. 111; no. 1; pp. 106 - 113
• Main Authors: Mohee, Amar, Khan, Ayisha, Harris, Neil, Eardley, Ian
• Format: Journal Article
• Language: English
• Published: Oxford Wiley-Blackwell 01.01.2013; Wiley Subscription Services, Inc
• Subjects: Administration, Intravesical; Biological and medical sciences; Botulinum Toxins, Type A - administration & dosage; Botulinum Toxins, Type A - adverse effects; detrusor overactivity; Female; Humans; intravesical botulinum toxin; Male; Medical sciences; Medication Adherence; Middle Aged; Nephrology. Urinary tract diseases; Neuromuscular Agents - administration & dosage; Neuromuscular Agents - adverse effects; OnabotulinumtoxinA; overactive bladder; Retrospective Studies; Treatment Outcome; Urinary Bladder, Neurogenic - drug therapy; Urinary Bladder, Overactive - drug therapy; Urinary Bladder, Overactive - etiology; Urinary system involvement in other diseases. Miscellaneous; Urinary tract. Prostate gland; Nephrology; Clostridium botulinum; Prognosis; Clostridiales; Metalloendopeptidases; Urology; Bontoxilysin; Urinary bladder; Bacteria; Overactive bladder; intravesical botulinum toxin; OnabotulinumtoxinA; Urinary system disease; Enzyme; detrusor overactivity; Urinary tract disease; Long term; Peptidases; Toxin; Treatment; Urinary system; Clostridiaceae; Hydrolases; Bladder disease; Intravesical administration

What's known on the subject? and What does the study add? It is known that intravesical botulinum toxin (BT) is an effective treatment for overactive bladder, especially in the patients with neurogenic detrusor overactivity. Several studies have shown that diagnostic and health‐related quality...